Novo Nordisk will sell a less expensive one-month supply of Wegovy for patients who previously took compounded versions of ...

Researchers are beginning to wonder if blockbuster drugs like Wegovy, Ozempic and Zepbound could play a role in preventing ...

The agreements cap monthly out-of-pocket costs for Zepbound and Wegovy at $200 and more deeply discount the drugs for ...

Researchers found GLP-1s may modestly reduce the risk of 14 obesity-related cancers, especially colorectal cancer, when compared to a weight-neutral medication used to treat diabetes.

Growing demand for natural weight loss solutions drives the weight management supplements market across health-conscious consumer segments.

Novo Nordisk reduced its starter dose prices through telehealth platforms to encourage patients to wean themselves off compounded copycats.

The CMS last month declined to include anti-obesity medications in its Medicare coverage for Part D, a move that Lilly says ...

Over the past six months, Eli Lilly has earned significant wins over its Denmark-based rival and is still at it. Recent clinical trial results Eli Lilly released suggest that it is building a lead in ...

Cigna’s (NYSE:CI) health services arm, Evernorth, has launched a pharmacy benefit program that caps out-of-pocket costs at $200 per month for patients using the weight-loss drugs - Wegovy from Novo ...

But the FDA declared months ago that the shortages of semaglutide and tirzepatide injections had ended, effectively ending ...

Cigna’s pharmacy benefits unit Evernorth said the deal will bring prices down for employers and their workers.